Story
Deutsche Bank Upgrades Aena to 'Hold' on Favorable Spanish Tariff Ruling

Summary
The German bank raised its rating from 'Sell' after Spain approved a 0.33% annual tariff increase for the airport operator, easing a key regulatory risk and prompting a price target increase to €24.
Deutsche Bank has upgraded Spanish airport operator Aena to 'Hold' from a previous 'Sell' rating, citing a favorable regulatory outcome that alleviates prior concerns. The bank also raised its price target on the stock to €24 from €20, according to a note from analyst Harishankar Ramamoorthy.
Tariff Approval Eases Risk
The upgrade follows a decision by Spain’s Council of Ministers to approve a 0.33% annual increase in airport tariffs under the new Dora III regulatory plan. This development marks a significant reversal of expectations for Deutsche Bank, which had previously forecast an approximate 2% annual decline in tariffs.
The bank's earlier bearish stance was based on a stronger passenger growth assumption of a 3.5% compound annual growth rate (CAGR) for the 2025-2031 period. The official projections in the Dora III plan are more conservative, easing the pressure for tariff reductions.
Details of the Dora III Framework
The Dora III plan outlines a total investment of approximately €13 billion for Aena. Key projections within the framework include:
Ad- Passenger numbers are forecast to grow from 321 million in 2025 to 346 million in 2031.
- This implies a modest CAGR of 1.3%, a significantly lower figure than Deutsche Bank had modeled.
- For context, Aena’s year-to-date passenger growth in Spain currently stands at 4.1%.
'Generous' Return on Assets
Deutsche Bank noted that the implied return allowed on Aena's regulatory asset base (RAB) under the new plan is likely to be above 8%. The analyst described this outcome as “generous,” considering Aena had initially sought a 9% return while the Spanish regulator, CNMC, had proposed 7.4%.
Despite the upgrade and increased price target, Aena’s shares last closed at €25 on September 15, trading slightly above the bank's new target. This valuation likely underpins the 'Hold' rating rather than a more bullish 'Buy' recommendation.
Read next
More on Stocks
Novo Nordisk, Orbis Medicines Ink $1.4 Billion Deal for Oral Cardiometabolic Drugs
Orbis Medicines and Novo Nordisk have entered a licensing collaboration potentially worth up to $1.4 billion to develop oral versions of injectable drugs for cardiometabolic diseases, leveraging Orbis's AI-driven discovery platform.

Robinhood Shares Rise After SEC Issues Guidance on Tokenized Securities
Shares of Robinhood Markets (HOOD) climbed after the U.S. Securities and Exchange Commission introduced a five-year plan allowing for the trading of tokenized stocks on designated venues.

Gold Prices Face Near-Term Pressure From Strong US Data, Higher Yields
Gold is trading in a narrow range as robust economic indicators bolster Treasury yields, creating headwinds for the non-yielding asset. The medium-term outlook remains constructive, contingent on a potential shift in monetary policy and persistent structural demand.

UBS Upgrades Industrial Metals to Overweight, Citing Long-Term Structural Tailwinds
UBS has raised its outlook on industrial metals to Overweight, arguing that structural forces like the energy transition and chronic underinvestment will support prices in the coming years.